Viagra vs Alprostadil (Caverject/MUSE): Titration Speed and Tolerability Compared

How Each Drug Produces an Erection

Sildenafil and alprostadil work through entirely different molecular pathways, and that difference determines everything about how they are titrated and tolerated.

Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor. It prolongs the effect of nitric oxide (NO) by blocking the enzyme that degrades cyclic GMP, which relaxes smooth muscle in the corpus cavernosum. The drug does nothing on its own, sexual stimulation must first trigger NO release. In men whose NO signaling is already impaired (severe diabetic neuropathy, post-prostatectomy), sildenafil may produce little response regardless of dose [1].

Alprostadil is a synthetic prostaglandin E1 (PGE1). It binds directly to EP receptors on cavernosal smooth muscle, raises intracellular cAMP, and relaxes smooth muscle without requiring any nitric-oxide input. That is why it works in men where PDE5 inhibitors have failed [2].

Why the Pathway Difference Matters for Titration

Because sildenafil depends on an intact NO axis, dose escalation above 100 mg rarely rescues a non-responder, you hit a ceiling of pharmacological use. With alprostadil, dose escalation reliably deepens the erection in most men because the drug acts directly and dose-dependently on the target tissue. Clinicians can titrate Caverject from 2.5 mcg up to 60 mcg and expect a graded response [3].

Receptor Selectivity and Systemic Effects

Sildenafil also weakly inhibits PDE6 (causing transient visual disturbance) and PDE1 (contributing to mild vasodilation and headache). Alprostadil's systemic absorption from intracavernosal injection is low, roughly 96% is metabolized on first pass through the pulmonary circulation, but MUSE delivers drug transurethrally, and a fraction reaches systemic circulation, occasionally causing hypotension [4].

Sildenafil Titration Protocol

Standard Dose Steps

The approved dose range for sildenafil is 25 mg, 50 mg, and 100 mg. Standard practice starts at 50 mg. If a man tolerates 50 mg without significant adverse effects but does not achieve adequate erection after two to three sexual attempts on separate occasions, the prescriber steps up to 100 mg. If 50 mg causes intolerable flushing or headache, the dose steps down to 25 mg [1].

This titration takes place at home. No in-office monitoring is required. The entire dose-finding process typically spans two to four weeks, the time needed to accumulate two or three real-world attempts at each dose level.

Optimizing Response Before Calling Sildenafil a Failure

A substantial fraction of men labeled "sildenafil non-responders" are actually "sildenafil misusers." Goldstein et al. (NEJM 1998, N=532) reported that 69% of men on 25 to 100 mg sildenafil achieved successful intercourse versus 22% on placebo (P<0.001), but compliance with dosing instructions, particularly taking the drug on an empty stomach and waiting the full 60 minutes, was tightly controlled in that trial [1].

Real-world response rates are lower. Men should be counseled to:

• Take sildenafil at least 60 minutes before sexual activity.
• Avoid a high-fat meal within two hours of dosing, which delays Tmax by up to 60 minutes.
• Attempt sex at least eight times at the maximum tolerated dose before concluding non-response [5].

Sildenafil Tolerability at Each Dose Level

The most common adverse effects in Goldstein et al. Were headache (16%), flushing (10%), dyspepsia (7%), and abnormal vision (3%) at the 100 mg dose [1]. These are generally mild and dose-dependent. Absolute contraindications include concurrent nitrate use (any formulation) and severe hepatic impairment; the drug is also contraindicated in men taking ritonavir or other strong CYP3A4 inhibitors without dose adjustment [5].

Alprostadil Caverject Titration Protocol

Why Caverject Titration Must Happen In-Office

Caverject (alprostadil injection) titration is not a home process. The initial dose and at least one dose-escalation step must be supervised by a clinician, because the primary risks, priapism and hypotension, require immediate intervention if they occur [3].

The standard in-office titration sequence:

1. Visit 1: Inject 2.5 mcg. Wait 30 minutes. Assess rigidity and duration.
2. Visit 2 (if inadequate response): Increase to 5 mcg. Assess again.
3. Subsequent visits: Increase in 5 to 10 mcg increments until the patient achieves an erection lasting no more than 60 minutes. That dose becomes the home dose.

Most men require two to three in-office visits. The effective dose for neurogenic erectile dysfunction (e.g., post-prostatectomy) typically falls between 2.5 and 20 mcg; men with vasculogenic ED often require 20 to 40 mcg [3].

Caverject Tolerability

In Linet et al. (NEJM 1996, N=296), 73% of Caverject injections resulted in erections adequate for intercourse versus 13% of placebo injections (P<0.001) [2]. The adverse-effect profile included:

• Penile pain: Reported after 37% of injections in the Linet trial; typically mild to moderate and transient [2].
• Prolonged erection (over four hours): Occurred in 1.3% of injection episodes in controlled trials [2].
• Penile fibrosis: Reported in 3 to 8% of long-term users in open-label extension data [3].
• Hematoma at injection site: Manageable with proper injection technique.

Men with a history of sickle cell disease, multiple myeloma, or leukemia should not use Caverject due to priapism risk. The drug is not contraindicated with nitrates, which is one reason it is preferred over sildenafil in men who need nitrate therapy for cardiovascular disease [3].

Injection Technique and Long-Term Adherence

Proper injection technique, inserting the needle at the lateral base of the penis, avoiding visible veins, alternating sides, substantially reduces the incidence of fibrosis and hematoma. Adherence declines over time; published series show 30 to 50% of men discontinue Caverject within one year, most commonly citing the inconvenience of injection or penile discomfort [6].

MUSE Titration Protocol

MUSE (medicated urethral system for erection) delivers alprostadil as a small pellet placed into the urethra using a prefilled applicator. It avoids injection but trades needle anxiety for a different set of tolerability issues.

MUSE Dose Steps

MUSE is available in four doses: 125 mcg, 250 mcg, 500 mcg, and 1,000 mcg. The prescribing information recommends that the first dose be administered in a physician's office to monitor for hypotension and syncope. Home titration then proceeds upward in 250 mcg increments until the patient identifies an effective dose [4].

Onset is 5 to 10 minutes. Duration is 30 to 60 minutes. The erection is generally less rigid than that produced by equivalent-dose Caverject, because a fraction of drug is lost to systemic absorption before reaching the corpora [4].

MUSE Tolerability Compared to Caverject

The most common adverse effect of MUSE is urethral pain or burning, reported by 30 to 36% of men in published series [4]. Hypotension sufficient to cause dizziness occurs in roughly 3% of men. Urethral bleeding (typically minor) occurs in about 5%. Female partners may experience vaginal burning from drug transfer, use of a condom is recommended when the partner is pregnant [4].

MUSE response rates in clinical trials are generally lower than Caverject. A crossover study published in Urology found that 70% of men who responded to Caverject failed to achieve adequate erection with MUSE at equivalent prostaglandin doses [7].

Head-to-Head Tolerability: A Side-by-Side Summary

The table below synthesizes tolerability data from key trials and published systematic reviews. Rates are approximate and vary by population.

| Parameter | Sildenafil 50 to 100 mg | Caverject 5 to 40 mcg | MUSE 250 to 1,000 mcg | |---|---|---|---| | Onset to erection | 30 to 60 min | 5 to 20 min | 5 to 10 min | | Requires sexual stimulation | Yes | No | No | | Headache | 16% | <1% | <1% | | Flushing | 10% | <1% | <1% | | Penile/urethral pain | <2% | 37% | 30 to 36% | | Priapism risk | <0.1% | 1.3% | 0.1 to 0.5% | | Penile fibrosis (long-term) | Not reported | 3 to 8% | Rare | | Systemic hypotension | Rare (contraindicated with nitrates) | Rare | 3% | | In-office titration needed | No | Yes (2 to 3 visits) | First dose only | | Contraindicated with nitrates | Yes | No | No |

Sources: [1][2][4][5]

Who Should Start With Alprostadil Instead of Sildenafil

Most guidelines, including the American Urological Association's 2018 guideline on erectile dysfunction, position PDE5 inhibitors as first-line therapy for ED in the absence of contraindications [5]. Alprostadil moves to first-line status in specific clinical situations.

Absolute Contraindication to PDE5 Inhibitors

Any man taking a nitrate, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, cannot safely use sildenafil or any PDE5 inhibitor due to risk of profound hypotension. Alprostadil carries no nitrate interaction and is the appropriate pharmacological choice [3].

Post-Radical Prostatectomy

Nerve-sparing radical prostatectomy still disrupts the cavernous nerves sufficiently that 40 to 60% of men experience significant ED, and many have impaired NO signaling. In this population, Caverject titrated from 2.5 mcg has a substantially higher response rate than sildenafil used alone [6]. Some clinicians use Caverject as part of penile rehabilitation protocols in the 12 months following surgery, though randomized evidence for that protocol remains limited [8].

Confirmed PDE5 Inhibitor Non-Response

A man who has completed eight or more attempts at 100 mg sildenafil under optimal conditions (fasting, adequate arousal, no nitrate use) and achieved no response is a confirmed PDE5 inhibitor non-responder at that agent. Switching within the PDE5 class, to tadalafil or avanafil, is reasonable, but adding or switching to Caverject is also appropriate at that juncture, and the AUA guideline supports this as a second-line option [5].

Switching From Sildenafil to Alprostadil: Practical Steps

Switching is not complicated, but it does require a return to in-office titration for Caverject.

1. Confirm the reason for switching. Document the number of sildenafil attempts, the dose used, and the conditions under which they occurred.
2. Rule out reversible causes. Testosterone deficiency, uncontrolled diabetes (HbA1c above 9%), and hypogonadism can blunt sildenafil response. Correcting these first may rescue PDE5-inhibitor efficacy [5].
3. Schedule Caverject titration. Start at 2.5 mcg regardless of age or severity. Do not extrapolate from sildenafil non-response to assume a high alprostadil dose is needed.
4. Provide injection training. Self-injection technique should be demonstrated in office and confirmed by the patient before home use is authorized.
5. Set realistic expectations. Caverject produces erections that do not depend on arousal, which some men and partners find less natural than the sildenafil experience. Discussing this preference before switching prevents early discontinuation.

Men should not take sildenafil and alprostadil on the same occasion. Combining them has not been studied in adequate controlled trials and may increase priapism risk [3].

Titration Speed: Which Drug Gets You to Effective Dosing Faster

Sildenafil can theoretically reach maximum approved dose in one week if a man attempts the drug twice at 50 mg and steps up. Realistically, most men spend three to six weeks working through the titration because sexual opportunities are limited.

Caverject titration in a motivated patient can reach the effective home dose within two to three weeks if visits are scheduled promptly. Each in-office visit takes 30 to 45 minutes including monitoring time.

From a purely time-to-effective-dose standpoint, both drugs take two to six weeks when scheduling and real-world sexual frequency are factored in. The difference is that sildenafil titration happens at home and Caverject titration requires a clinician's presence for safety monitoring.

The AUA guideline states: "Intracavernosal injection therapy is effective and may be offered as a second-line therapy for men who do not respond to or cannot use PDE5i" [5]. That positioning reflects both tolerability burden and titration complexity rather than any inferiority in efficacy.

Long-Term Considerations

Long-term sildenafil use at doses of 25 to 100 mg is well-characterized. The NEJM key trial showed no cumulative toxicity signal over the 24-week study period, and post-marketing data spanning more than two decades do not show organ toxicity in men without significant cardiovascular contraindications [1].

Long-term Caverject use carries a small but real risk of penile fibrosis. Published series report rates of 3 to 8% over one to three years of use [3]. Annual penile examination is recommended for men on long-term intracavernosal therapy. If palpable plaques develop, the drug should be discontinued and urology evaluation arranged, as fibrosis can progress to Peyronie disease.

MUSE's long-term tolerability profile is less well-characterized in the literature. Given that systemic absorption is higher than with injection, men with significant cardiovascular disease or orthostatic hypotension should be monitored more carefully during dose titration [4].